WBWilliam Beaubien-Souligny

William Beaubien-Souligny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Beaubien-Souligny has a total of 291 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Pilot Randomized Controlled Trial of Ultrasound Evaluation of Fluid Tolerance for Acute Kidney Injury

    by Michel Gouin, Karel Huard, Alicia Shen, Jean-Maxime Côté, André Denault, William Beaubien-Souligny

    Key Points: Point-of-care ultrasound could provide important information to guide fluid administration in AKI. This study demonstrates the feasibility assessing fluid tolerance through lung and venous ultrasound and implementing it in a trial. Point-of-care ultrasound influenced management in half of patients and lead to higher rate of early diuretic use without negatively affecting kidney function. Background: Indiscriminate fluid administration in AKI can be harmful, and point-of-care ultrasound (POCUS) could be used to assess for fluid tolerance. The objective of pilot study was to determine the feasibility of a randomized trial comparing a fluid management strategy, including POCUS, with usual care. Methods: This is a single-center, open-label, pilot randomized controlled trial that recruited noncritically ill patients with AKI for whom fluid administration had begun or was considered. The intervention consisted in the transmission to the nephrology team of a POCUS report on fluid tolerance (assessment of pulmonary B-lines and systemic venous congestion with the venous excess ultrasound score). The control was usual care without POCUS. The primary outcome was feasibility, defined as protocol adherence. Results: Eighty patients underwent randomization, 40 were randomized in the POCUS group and 40 in the usual care group, but one withdrew consent before initiating trial procedures. Protocol adherence was achieved in all patients. In the intervention arm, 50% of initial ultrasound reports led to a change in clinical conduct, and the provided information was perceived as useful by clinicians (median 4.5/5 [interquartile range, 4.0–5.0]). The intervention led to a higher use of diuretics during the first day after randomization (40% versus 15%, P = 0.01), but did not result in difference in cumulative fluid balance or diuretic use at 5 days, progression to higher stages of AKI, or composite outcome of death and escalation of care. Conclusions: This pilot trial demonstrate the feasibility of a randomized trial investigating the clinical effect of providing a POCUS fluid tolerance evaluation in AKI. Its effect on clinical management and perceived usefulness support the rationale for future, larger-scale studies. Clinical Trial registry name and registration number: NCT06411080.


  • Open Access

    Intra-Dialytic Hypotension and the VExUS Assessment in Hospitalized Patients: A Prospective Cohort Study

    by Rose Joyal, Josiane Proulx, Michel Gouin, Karel Huard, Lawrence Ledoux-Hutchinson, Sophie Gilbert, Emmanuel Charbonney, André Denault, William Beaubien-Souligny

    Introduction: Predicting tolerance to fluid removal is particularly challenging in hospitalized, acutely ill patients. This study evaluated the association between the Venous Excess Ultrasound (VExUS) and IDHE in hospitalized patients. Methods: This single-center prospective cohort included hospitalized between 2022 and 2024 receiving hemodialysis. Ultrasound of the inferior vena cava (IVC), hepatic, portal, and femoral veins was performed. Patients were classified into four VExUS grades (0 to 3) based on IVC dimensions and venous Doppler waveforms. Follow-up at 3 months was conducted to evaluate outcomes across the different groups. Results: The cohort consisted of 93 patients. VExUS grading showed grade 0 in 52 patients (55.9%), grade 1 in 22 patients (23.7%), grade 2 in 11 patients (11.8%), and grade 3 in 8 patients (8.6%). The incidence of IDHE was tended to be higher in VExUS grade 0 (40.4%) and VExUS grade 3 (50.0%) patients compared with VExUS grade 1 (18.2%) or 2 (18.2%) (p = 0.145). The cumulative duration of hypotension (sBP <90 mm Hg) differed between VExUS groups (p = 0.03), with VExUS grade 3 patients experiencing longer median duration of hypotension compared to participants with a VExUS grade 1 (16.4 [0; 47.5] vs. 0 [0; 0] min, p = 0.04). Conclusion: Our findings showed a trend toward more frequent IDHE in both VExUS grade 0 and grade 3, with grade 3 patients experiencing a significantly longer cumulative duration of hypotension. High VExUS scores may identify patients at increased risk of hypotension due to impaired hemodynamic adaptability.


  • Open Access

    Proactive Prescription-Based Fluid Management Versus Usual Care in Critically Ill Patients on Kidney Replacement Therapy (Probe-Fluid): A Pilot Clinical Trial Protocol

    by Alicia Shen, Josée Bouchard, Javier A. Neyra, François Lamontagne, Jean-Maxime Côté, Edward G. Clark, Bruno R. da Costa, Martin Gallagher, Neill K. J. Adhikari, Samuel A. Silver, et al.

    Background: Severe acute kidney injury (AKI) in the intensive care unit (ICU) is complicated by fluid accumulation, making fluid removal a central component of kidney replacement therapy (KRT). However, the optimal fluid management strategy in patients receiving KRT remains unknown, and practice varies widely. Objective: To assess the feasibility of conducting a multicentre randomized controlled trial comparing a protocol-based fluid-removal strategy with usual care in critically ill adult patients receiving KRT. The primary objective is to determine whether the intervention results in a difference in cumulative fluid balance from randomization to day five. Design: Open-label, multicentre, pilot randomized controlled trial. Setting: Centers in Canada, the United States, and Australia. Patients: We are enrolling 150 adults admitted to the ICU with AKI who have been receiving KRT for ≤48 hours or who are anticipated to commence KRT within the next 12 hours. Measurements: The primary outcome is the difference in cumulative fluid balance (mL) between treatment arms from randomization (day zero) to the end of day five. Secondary outcomes include feasibility metrics, patient outcomes, resource use, safety outcomes, and process measures. Methods: Participants are randomized 1:1 to receive either protocol-based fluid management or usual care. The intervention consists of a prescription template updated at least once daily by the attending care team, specifying a 24-hour fluid balance target, a prescription for fluid removal using KRT, and daily re-evaluation of fluid intake. The intervention is continued until day five post-randomization, KRT discontinuation due to kidney recovery, or ICU discharge. Limitations: The application of the intervention relies on the clinical judgment of the attending care team, which may affect the fidelity of the intervention. Usual care may differ between institutions, which may lead to variability. The treatment teams are unblinded, however the statistician will be blinded to group allocation. Conclusions: The Probe-Fluid pilot trial will provide important groundwork toward a future definitive multicentre randomized controlled trial comparing a protocol-based fluid management strategy with usual care in critically ill patients receiving KRT.

  • Open Access

    Proceedings of the University of Alabama at Birmingham Continuous Renal Replacement Therapy Academy (2023–2024)

    by William Beaubien-Souligny, Melissa Thompson Bastin, J. Pedro Teixeira, Jorge Cerda, Michael J. Connor, Amanda Dijanic Zeidman, Pranav S. Garimella, Luis Juncos, Arnaldo Lopez-Ruiz, Ravindra Mehta, et al.

    In this second installment of the proceedings of the University of Alabama at Birmingham Continuous Renal Replacement Therapy (CRRT) Academy, we focus on the topic of transitions of care in acute renal replacement therapy (RRT). Although we have accumulated data from thousands of critically ill patients with AKI randomized to different strategies for RRT initiation, no trial data exist to guide de-escalation of RRT in the intensive care unit. However, for survivors of severe AKI whose kidney function does not recovery rapidly enough to allow for liberation directly from CRRT, successful de-escalation of care requires the transition from CRRT to intermittent RRT modalities. These transition periods must be carefully navigated since they can be a source of complications, such as failure to transition or intradialytic hypotension, which are in turn associated with an increased risk of mortality and reduced odds of kidney recovery. In this review, we focus on the critical factors to consider during de-escalation of RRT care, with a focus on modality transition, the role of volume status in guiding the approach to de-escalation of RRT, and the vital importance of careful dosing of drugs, especially antimicrobial agents, during this transitional period.


  • Renal and Urinary Bladder Ultrasound

    by Eduardo R. Argaiz, William Beaubien-Souligny, Abhilash Koratala

  • Open Access

    Sample Size of Trials Investigating the Impact of Point‐of‐Care Ultrasound‐Guided Strategies on Patient Outcomes

    by William Beaubien‐Souligny, Michel Gouin, Karel Huard

    Point‐of‐care ultrasound (POCUS) is increasingly utilized for bedside diagnosis and management in diverse clinical contexts. However, the design of randomized controlled trials (RCTs) evaluating the impact of POCUS‐guided strategies on clinical outcomes presents significant challenges. This study aims to explore the assumptions underlying sample size estimation in POCUS‐guided trials and assess the adequacy of sample sizes in published trials through a systematic review. We performed a sample size analysis considering varying rates of POCUS‐induced management changes and plausible effect sizes on binary and continuous patient‐centered outcomes. Additionally, a systematic review of PubMed was conducted to identify RCTs comparing POCUS‐guided management to usual care, extracting data on planned and actual sample sizes and justifications for sample size decisions. Sample size estimations revealed a substantial dependence on the proportion of participants experiencing management changes due to POCUS findings. For example, achieving adequate power in a trial with a moderate effect size requires over 1000 participants if POCUS alters management in 50% of cases. Our review included 25 RCTs, with a median sample size of 206 participants (interquartile range 122–250). Only 68% of trials reported sample size justifications, and 41% failed to meet planned recruitment targets, primarily due to recruitment challenges and other logistical barriers. Most trials investigating POCUS‐guided strategies are underpowered, underscoring the need for realistic sample size estimations that consider the rate of POCUS‐induced management changes and anticipated effect sizes. Future trials should incorporate pilot phases and innovative designs to optimize feasibility and power.


  • Open Access

    Trajectories of fluid management after the initiation of renal replacement therapy in critically ill patients: a secondary analysis of the STARRT-AKI trial

    by William Beaubien-Souligny, Ehsan Gamarian, Jean-Maxime Côté, Javier A. Neyra, Frederic Baroz, Neill K. J. Adhikari, Kevin Thorpe, Sean M. Bagshaw, Ron Wald

    Background: Fluid management is an essential component of renal replacement therapy (RRT) in critically ill patients. Both a positive cumulative fluid balance (CFB) and a high net ultrafiltration (NUF) rate have been reported to be associated with adverse outcomes in epidemiological studies, although the overall trajectory of fluid balance after RRT initiation is not well-described. We aimed to characterize trajectories of fluid management parameters during RRT and analyse the effect of CFB/NUF on outcomes as a trajectory rather than single or aggregated time points over the first week after initiation of RRT. Methods: This is a secondary analysis using fluid balance data focusing on individuals enrolled in the standard-strategy arm of the STARRT-AKI trial who initiated RRT. Cumulative fluid balance (CFB) following RRT initiation and daily net ultrafiltration (NUF) adjusted for body weight during the first 7 days after initiation of RRT were the main independent exposures. We modeled the trajectory of fluid parameters using spline functions and used latent trajectory analysis methods to identify predominant trajectories to compare patients’ characteristics and outcomes. We employed logistic regression and multivariable joint longitudinal models to compare the odds and determine the time-dependent association between fluid parameters (CFB and NUF) and 90-day mortality across and within the trajectory classes identified. Results: We included 855 patients in the primary analysis. After excluding erroneous fluid balance data, we identified two distinct CFB/NUF trajectories. Class A (82.8%) was characterized by a slight increase in CFB and low/stable NUF during the week following RRT initiation while class B (17.2%) was characterized by an increasingly negative CFB with initially higher daily NUF during the first 4 days followed by a stabilization after day 4. In an adjusted analysis, individuals classified in class B were at lower risk for 90-day mortality (aOR: 0.48 CI 0.32; 0.70) p < 0.001) compared to class A. Time-dependent analysis revealed higher CFB was associated with mortality only in those with a class A trajectory (aHR 1.29, 95% CI 1.03–1.55, p = 0.03). Conclusions: Distinct CFB/NUF trajectories convey prognostic information beyond single-day fluid balance or NUF values and should be considered when formulating or interpreting fluid management strategies.


  • Open Access

    Venous Excess Doppler ultrasound assessment and loop diuretic efficiency in acute cardiorenal syndrome

    by Eslam Abu-Naeima, Moataz Fatthy, Mahmoud Amin Abu-Sheaishaa Shalaby, Ghada Ayeldeen, Frederik H. Verbrugge, Philippe Rola, William Beaubien-Souligny, Ahmed Fayed

    Background: Cardiorenal syndrome poses significant diagnostic and therapeutic challenges. The Venous Excess Ultrasound (VExUS) grading system based on the combination of venous Doppler assessments has shown potential in predicting acute kidney injury and cardiovascular outcomes, but its relevance regarding the management of acutely decompensated heart failure (ADHF) remains to be fully understood. Methods: In this prospective study, patients with ADHF and acute kidney injury (AKI) were enrolled from a medical intensive care unit over 20 months. The study involved echocardiography and VExUS grading at admission and 72 h later. Data collection included clinical parameters, diuretic dosages, urine output, and fluid balance. Statistical analyses focused on exploring the relationships between VExUS grades and its components, including the renal venous stasis index (RVSI), diuretic efficiency, and renal function improvement. Results: The cohort of 43 patients showed varied VExUS grades at admission. Higher VExUS grades were significantly associated with lower diuretic efficiency. Specifically, the mean urine output per 40 mg of furosemide was 368 ± 213 mL, with patients having VExUS grade 2 or 3 exhibiting reduced diuretic efficiency compared to those with grade 0–1 (Grade 2 vs. Grade 0–1: 333 ± 214 mL vs. 507 ± 189 mL, p = 0.02; Grade 3 vs. Grade 0–1: 270 ± 167 mL vs. 507 ± 189 mL, p = 0.004). The relationship between VExUS grade and diuretic efficiency was independent of admission creatinine and prior use of loop-diuretics (β = -106 CI: -180; -32 p = 0.006). Among the components of venous congestion assessment, the RVSI had the best ability to predict low diuretic efficiency (AUROC: 0.76 (0.60; 091) p = 0.001). Improvement in VExUS grade at 72 h was correlated with significant renal function improvement (84.6% vs. 47.1% for improved vs. non-improved VExUS grades, p = 0.03). Conclusion: High VExUS and RVSI grades at admission are independently associated with reduced diuretic efficiency in ADHF patients with AKI. The findings emphasize the clinical value of venous congestion assessment in cardiorenal syndrome management including the selection of an initial diuretic dose.


  • Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis

    by Ziv Harel, Brendan Smyth, Sunil V. Badve, Daniel Blum, William Beaubien-Souligny, Samuel A. Silver, Edward Clark, Rita Suri, Thomas A. Mavrakanas, Joanna Sasal, et al.

    Key Points: Is performing a large definitive trial to establish the optimal anticoagulation strategy in dialysis recipients with atrial fibrillation feasible? One hundred fifty-one patients at 28 dialysis centers were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Despite coronavirus disease–related pauses, recruitment was completed in 30 months, with 83% of participants completing follow-up in their assigned treatment arm. Background: Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. Methods: The Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis trial was a parallel-group, open-label, allocation-concealed, pilot randomized control trial that took place at 28 centers in Canada and Australia. The trial included adults (18 years or older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 criteria. Participants were randomized 1:1:1 to receive dose-adjusted warfarin, apixaban 5 mg twice daily, or no oral anticoagulation and followed for 26 weeks. The primary outcomes evaluated the following measures of feasibility: ( 1 ) recruitment of the target population within 2 years from the start of the trial and ( 2 ) adherence of >80% of randomized patients to the allocated treatment strategy at the conclusion of follow-up. Secondary outcomes included stroke and bleeding. Results: From December 2019 to June 2022, 151 patients were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Allowing for pauses related to the coronavirus disease pandemic, recruitment was completed in 30 months, and 123 (83%) of participants completed follow-up in their allocated treatment arm. There was one adjudicated stroke event. Eight participants had a major bleeding event (four warfarin, two apixaban, two no oral anticoagulation). Death occurred in 15 participants (nine warfarin, two apixaban, four no oral anticoagulation). Time in the therapeutic range for warfarin recipients was 58% (interquartile range, 47%–70%). Conclusions: We have demonstrated the feasibility of recruitment and adherence in a trial that compared different anticoagulation strategies in patients with atrial fibrillation receiving dialysis. Clinical Trial registry name and registration number: Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis (SAFE-D), NCT03987711. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3


  • Open Access

    Protocolized fluid balance neutralization during continuous renal replacement therapy

    by Raghavan Murugan, John Prowle, William Beaubien-Souligny